Neovacs' TNF-Kinoid moves into Phase II in Crohn's disease
This article was originally published in Scrip
Executive Summary
Neovacs has begun a Phase II multicentre international clinical trial of its TNF-alpha Kinoid product for patients with Crohn's disease. Following the results of its Phase I/II study announced at the beginning of December 2010, the company received the go-ahead from regulatory authorities and ethics committees in France and Belgium. Neovacs' CEO, Guy Charles Fanneau de la Horie, told Scrip that the company was expecting trial approvals in a number of other European countries and that patient recruitment there, as well as in France and Belgium, would be completed by the end of March 2011.